Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries
CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience Therapeutics Company of the Year” in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies.
Emalex Biosciences is currently conducting a registrational Phase 3 trial of its lead candidate, ecopipam, for patients with Tourette Syndrome. The therapeutic is a new class of drug that blocks the actions of the neurotransmitter dopamine at the D1 receptor, as opposed to the currently approved therapies for the treatment of Tourette’s which act on D2 receptors. Patients in clinical trials to date did not have observable evidence of adverse movements, excessive weight gain, or metabolic side effects commonly reported with drugs that target the D2 receptors. The most frequent adverse events related to ecopipam are headache (15.8%), insomnia (14.5%), fatigue (7.9%), and somnolence (7.9%).
“The results of our studies are encouraging and inspire all of us to continue this important work towards a safe and effective therapy for patients living with Tourette,” said Eric Messner, CEO at Emalex Biosciences. “We’re thankful to BioTech Breakthrough for recognizing our passion for innovating solutions that improve the lives of people living with chronic CNS conditions. We hope to bring them a potentially life-changing therapy.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets. This year’s program attracted thousands of nominations from over 14 different countries, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“Emalex Biosciences is helping people with Tourette Syndrome to find relief from the tics that not only cause pain and injury but also social stigma and emotional distress. Almost one out of every 160 children in the U.S. has Tourette, with symptoms continuing into adulthood for many. In addition to being associated with increased mortality, it impacts the day-to-day physical and social function of patients,” said Bryan Vaughn, managing director, BioTech Breakthrough. “Emalex is giving hope to patients struggling to find first-line treatments that don’t come with poorly tolerated side effects and we’re proud to present Emalex with the ‘Neuroscience Therapeutics Company of the Year’ award.”
About Emalex Biosciences
Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Emalex is in late-stage development of a new class of drug targeting the D1 receptor for patients with Tourette syndrome and other conditions that have limited treatment options. Visit https://emalexbiosciences.com/ to learn more.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Media Contact:
Sheridan Chaney
312.847.1323
sc@paragonbiosci.com